Crossmark

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Crossref DOI link: https://doi.org/10.1038/s41375-018-0112-2

Published Online: 2018-03-29

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hosseini, Mona M.

Kurtz, Stephen E.

Abdelhamed, Sherif

Mahmood, Shawn

Davare, Monika A.

Kaempf, Andy

Elferich, Johannes

McDermott, Jason E.

Liu, Tao

Payne, Samuel H. http://orcid.org/0000-0002-8351-1994
Shinde, Ujwal

Rodland, Karin D.

Mori, Motomi

Druker, Brian J.

Singer, Jack W.

Agarwal, Anupriya
License Information

Text and Data Mining valid from 2018-03-29
More Information

Article History

Received: 11 September 2017

Revised: 5 March 2018

Accepted: 13 March 2018

First Online: 29 March 2018

Compliance with ethical standards

:

: JWS is employed by and has equity ownership in CTI BioPharma, Corp. The authors report no other potential conflicts of interest to declare.